Susanne Hoeppner, GM of Astellas Switzerland and board member of vips, discusses her key priorities, the culture of Swiss pharma, and the industry-wide push for faster approval times.
Ms. Hoeppner, in addition to your role as general manager of Astellas, we understand you also have leadership role within the industry as a board member of the Association of Pharmaceutical Companies in Switzerland (vips). What are some of your key priorities in this capacity?
"Swiss culture is generally tuned towards innovation and quality, and Switzerland is ranked the most innovative country in Europe and the world by many indexes. This mentality very much affects the way medicines are prescribed and consumed."
